This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

GSK-1614235

GlaxoSmithKline plc

Drug Names(s): GSK1614235, DSP-3235, KGA-3235

Description: DSP-3235 is a sodium glucose transporter-1 (SGLT-1) inhibitor.

Deal Structure: Dainippon and Kissei
In March 2008, Dainippon licensed the drug from Kissei.

In July 2011, Dainippon discontinued its development of DSP-3235. Additionally, the Company no longer lists DSP-3235 in its pipeline. As a result, we believe the partnership between Kissei and Dainippon has been cancelled.

GlaxoSmithKline and Kissei
In June 2008, Kissei concluded an agreement with GlaxoSmithKline on the KGT compounds discovered and developed by Kissei, to grant exclusive development and sales right in Japan, South Korea, Taiwan and China.

Partners: Kissei Pharmaceutical Co., Ltd


GSK-1614235 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug